Added to YB: 2025-02-18
Pitch date: 2024-12-31
ARQT [bullish]
Arcutis Biotherapeutics, Inc.
+104.37%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Market Cap
$3.1B
Pitch Price
$14.20
Price Target
39.00 (+34%)
Dividend
N/A
EV/EBITDA
-92.02
P/E
-71.30
EV/Sales
9.39
Sector
Biotechnology
Category
growth
Show full summary:
Arcutis Biotherapeutics, Inc. - $ARQT
ARQT: Zoryve drug for PP, SD, AD showing strong growth. 18,255 weekly scripts, $367M run-rate vs $268M 2025 est. Peak sales $1.58B. Kowa deal expands TAM to 11.9M patients. Trading at 9.1x 2026E, 6.6x 2027E, 1x peak sales. $39 PT (180% upside) at 3x peak sales. Catalysts: script growth, consensus revisions.
Read full article (4 min)